Sangamo Therapeutics Inc (SGMO)
0.5463
-0.01
(-1.59%)
USD |
NASDAQ |
Apr 16, 15:34
Sangamo Therapeutics Cash from Operations (TTM): -224.84M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -224.84M |
| September 30, 2023 | -231.35M |
| June 30, 2023 | -237.68M |
| March 31, 2023 | -230.95M |
| December 31, 2022 | -223.63M |
| September 30, 2022 | -219.29M |
| June 30, 2022 | -225.09M |
| March 31, 2022 | -223.68M |
| December 31, 2021 | -233.25M |
| September 30, 2021 | -184.83M |
| June 30, 2021 | -92.34M |
| March 31, 2021 | 120.22M |
| December 31, 2020 | 169.88M |
| September 30, 2020 | 153.35M |
| June 30, 2020 | 81.41M |
| March 31, 2020 | -118.17M |
| December 31, 2019 | -144.40M |
| September 30, 2019 | -163.75M |
| June 30, 2019 | -152.47M |
| March 31, 2019 | 9.565M |
| December 31, 2018 | 36.55M |
| September 30, 2018 | 59.87M |
| June 30, 2018 | 71.78M |
| March 31, 2018 | 6.123M |
| December 31, 2017 | 11.18M |
| Date | Value |
|---|---|
| September 30, 2017 | 16.25M |
| June 30, 2017 | 14.36M |
| March 31, 2017 | -58.60M |
| December 31, 2016 | -65.88M |
| September 30, 2016 | -63.22M |
| June 30, 2016 | -59.84M |
| March 31, 2016 | -51.69M |
| December 31, 2015 | -33.72M |
| September 30, 2015 | -27.33M |
| June 30, 2015 | -18.90M |
| March 31, 2015 | -19.45M |
| December 31, 2014 | -5.675M |
| September 30, 2014 | -4.62M |
| June 30, 2014 | -3.366M |
| March 31, 2014 | -0.085M |
| December 31, 2013 | -19.48M |
| September 30, 2013 | -17.60M |
| June 30, 2013 | -18.25M |
| March 31, 2013 | -18.97M |
| December 31, 2012 | -8.082M |
| September 30, 2012 | -8.303M |
| June 30, 2012 | -9.612M |
| March 31, 2012 | -11.07M |
| December 31, 2011 | -25.90M |
| September 30, 2011 | -28.47M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-237.68M
Minimum
Jun 2023
169.88M
Maximum
Dec 2020
-125.31M
Average
-184.83M
Median
Sep 2021
Cash from Operations (TTM) Benchmarks
| AIM ImmunoTech Inc | -21.27M |
| Perspective Therapeutics Inc | -36.91M |
| Protalix BioTherapeutics Inc | -1.318M |
| Electromed Inc | 4.872M |
| Armata Pharmaceuticals Inc | -47.42M |